For decades, patients diagnosed with advanced-stage follicular lymphoma, a slow-growing type of blood cancer, have been told the same difficult truth: the disease is incurable. It can be treated and managed, but it almost always comes back. A major new SWOG analysis, just published in JAMA Oncology, is challenging that long-held assumption in a meaningful way.
Researchers applied a sophisticated statistical method called cure modeling to 15 years of follow-up data from the S0016 clinical trial, which enrolled patients with advanced-stage follicular lymphoma beginning in 2001. About 70 percent of patients remained alive 15 years after starting treatment, and the cure modeling estimated that 42 percent of treated patients had been cured, meaning they have no chance of the lymphoma recurring during their expected lifespan.
Lead author Dr. Jonathan Friedberg called these findings a “paradigm shift” in the understanding of follicular lymphoma. The results suggest that a substantial subset of patients, when treated with a standard regimen combining immunotherapy and chemotherapy, can achieve long-term disease control after a time-limited course of treatment. This could change how newly diagnosed patients are counseled and could eliminate the need for indefinite oncology and radiologic follow-up visits, with patients eventually transitioning from oncology care back to a primary care team.
